PRENDERGAST FRANKLYN G 4
4 · Immunome Inc. · Filed Oct 4, 2023
Insider Transaction Report
Form 4
Immunome Inc.IMNM
PRENDERGAST FRANKLYN G
Director
Transactions
- Award
Common Stock
2023-10-02+60,840→ 60,840 total - Award
Stock Option (Right to Buy)
2023-10-02$1.35/sh+137,725$185,929→ 137,725 totalExercise: $1.35Exp: 2032-09-26→ Common Stock (137,725 underlying)
Footnotes (2)
- [F1]In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.
- [F2]In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable.